全文获取类型
收费全文 | 9718篇 |
免费 | 675篇 |
出版年
2021年 | 103篇 |
2020年 | 54篇 |
2019年 | 70篇 |
2018年 | 134篇 |
2017年 | 97篇 |
2016年 | 151篇 |
2015年 | 212篇 |
2014年 | 287篇 |
2013年 | 517篇 |
2012年 | 444篇 |
2011年 | 491篇 |
2010年 | 261篇 |
2009年 | 271篇 |
2008年 | 483篇 |
2007年 | 432篇 |
2006年 | 424篇 |
2005年 | 422篇 |
2004年 | 433篇 |
2003年 | 404篇 |
2002年 | 426篇 |
2001年 | 364篇 |
2000年 | 373篇 |
1999年 | 301篇 |
1998年 | 139篇 |
1997年 | 102篇 |
1996年 | 105篇 |
1995年 | 110篇 |
1994年 | 83篇 |
1993年 | 73篇 |
1992年 | 227篇 |
1991年 | 237篇 |
1990年 | 202篇 |
1989年 | 207篇 |
1988年 | 162篇 |
1987年 | 142篇 |
1986年 | 121篇 |
1985年 | 132篇 |
1984年 | 113篇 |
1983年 | 115篇 |
1982年 | 94篇 |
1981年 | 72篇 |
1980年 | 53篇 |
1979年 | 80篇 |
1978年 | 84篇 |
1977年 | 61篇 |
1976年 | 75篇 |
1975年 | 56篇 |
1973年 | 60篇 |
1972年 | 43篇 |
1971年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
Toshio Watanabe Toshihisa Takeuchi Osamu Handa Yasuhisa Sakata Tetsuya Tanigawa Masatsugu Shiba Yuji Naito Kazuhide Higuchi Kazuma Fujimoto Toshikazu Yoshikawa Tetsuo Arakawa 《PloS one》2015,10(4)
Background
Low-dose aspirin (LDA) frequently causes small bowel injury. While some drugs have been reported to be effective in treating LDA-induced small intestinal damage, most studies did not exclude patients with mild damage thought to be clinically insignificant.Aim
We conducted a multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy of a high dose of rebamipide, a gastroprotective drug, for LDA-induced moderate-to-severe enteropathy.Methods
We enrolled patients who received 100 mg of enteric-coated aspirin daily for more than 3 months and were found to have more than 3 mucosal breaks (i.e., erosions or ulcers) in the small intestine by capsule endoscopy. Eligible patients were assigned to receive either rebamipide 300 mg (triple dose) 3 times daily or placebo for 8 weeks in a 2:1 ratio. Capsule endoscopy was then repeated. The primary endpoint was the change in the number of mucosal breaks from baseline to 8 weeks. Secondary endpoints included the complete healing of mucosal breaks at 8 weeks and the change in Lewis score (an endoscopic score assessing damage severity) from baseline to 8 weeks.Results
The study was completed by 38 patients (rebamipide group: n = 25, placebo group: n = 13). After 8 weeks of treatment, rebamipide, but not placebo, significantly decreased the number of mucosal breaks (p = 0.046). While the difference was not significant (p = 0.13), the rate of complete mucosal break healing in the rebamipide group (32%, 8 of 25) tended to be higher than that in the placebo group (7.7%, 1 of 13). Rebamipide treatment significantly improved intestinal damage severity as assessed by the Lewis score (p = 0.02), whereas placebo did not. The triple dose of rebamipide was well tolerated.Conclusions
High-dose rebamipide is effective for the treatment of LDA-induced moderate-to-severe enteropathy.Trial Registration
UMIN Clinical Trials Registry UMIN000003463 相似文献972.
973.
Ryutaro Kakinuma Noriyuki Moriyama Yukio Muramatsu Shiho Gomi Masahiro Suzuki Hirobumi Nagasawa Masahiko Kusumoto Tomohiko Aso Yoshihisa Muramatsu Takaaki Tsuchida Koji Tsuta Akiko Miyagi Maeshima Naobumi Tochigi Shun-ichi Watanabe Naoki Sugihara Shinsuke Tsukagoshi Yasuo Saito Masahiro Kazama Kazuto Ashizawa Kazuo Awai Osamu Honda Hiroyuki Ishikawa Naoya Koizumi Daisuke Komoto Hiroshi Moriya Seitaro Oda Yasuji Oshiro Masahiro Yanagawa Noriyuki Tomiyama Hisao Asamura 《PloS one》2015,10(12)
974.
975.
Sohee Shin Shinichi Demura Tsuneo Watanabe Tamotsu Yabumoto Jae-Hyun Lee Naoki Sakakibara Toshio Matsuoka 《Journal of physiological anthropology》2015,34(1)
Background
This study aims to examine age-related and obstacle height-related differences in movements while stepping over obstacles.Methods
The participants included 16 elderly and nine young women. Obstacles that were either 5 or 20 cm high were positioned at the center of a 4-m walking path. The participants were instructed to walk along the path as quickly as possible. The participants’ movements were analyzed using a three-dimensional motion analysis system that recorded their movements as they walked and stepped over the obstacles.Results and conclusions
Seven joint angles and the distances between the ground and six markers were examined in the initial contact and swing instants of the leading and trailing limbs. In the initial contact instant, the elderly women prepared for stepping with a lower toe height than the young women when stepping over the 20-cm obstacle. Trunk rotation was greater in the young women than in the elderly women. In the swing instant, the elderly women showed greater ankle dorsiflexion and hip adduction angles for the leading limb when stepping over the 20-cm obstacle. They moved the trailing limb with increased ankle dorsiflexion, knee flexion, hip flexion, and foot inversion to ensure that they did not touch the obstacle as they stepped over it. These movement patterns are characteristic of elderly individuals who cannot easily lift their lower limbs because of decreased lower-limb strength. 相似文献976.
Akiko Takasuga Kunio Sato Ryouichi Nakamura Yosuke Saito Shinji Sasaki Takehito Tsuji Akio Suzuki Hiroshi Kobayashi Tamako Matsuhashi Koji Setoguchi Hiroshi Okabe Toshitake Ootsubo Ichiro Tabuchi Tatsuo Fujita Naoto Watanabe Takashi Hirano Shota Nishimura Toshio Watanabe Makio Hayakawa Yoshikazu Sugimoto Takatoshi Kojima 《PLoS genetics》2015,11(8)
Recessive skeletal dysplasia, characterized by joint- and/or hip bone-enlargement, was mapped within the critical region for a major quantitative trait locus (QTL) influencing carcass weight; previously named CW-3 in Japanese Black cattle. The risk allele was on the same chromosome as the Q allele that increases carcass weight. Phenotypic characterization revealed that the risk allele causes disproportional tall stature and bone size that increases carcass weight in heterozygous individuals but causes disproportionately narrow chest width in homozygotes. A non-synonymous variant of FGD3 was identified as a positional candidate quantitative trait nucleotide (QTN) and the corresponding mutant protein showed reduced activity as a guanine nucleotide exchange factor for Cdc42. FGD3 is expressed in the growth plate cartilage of femurs from bovine and mouse. Thus, loss of FDG3 activity may lead to subsequent loss of Cdc42 function. This would be consistent with the columnar disorganization of proliferating chondrocytes in chondrocyte-specific inactivated Cdc42 mutant mice. This is the first report showing association of FGD3 with skeletal dysplasia. 相似文献
977.
Shusuke Numata Kazuo Ishii Atsushi Tajima Jun-ichi Iga Makoto Kinoshita Shinya Watanabe Hidehiro Umehara Manabu Fuchikami Satoshi Okada Shuken Boku Akitoyo Hishimoto Shinji Shimodera Issei Imoto Shigeru Morinobu Tetsuro Ohmori 《Epigenetics》2015,10(2):135-141
Aberrant DNA methylation in the blood of patients with major depressive disorder (MDD) has been reported in several previous studies. However, no comprehensive studies using medication-free subjects with MDD have been conducted. Furthermore, the majority of these previous studies has been limited to the analysis of the CpG sites in CpG islands (CGIs) in the gene promoter regions. The main aim of the present study is to identify DNA methylation markers that distinguish patients with MDD from non-psychiatric controls. Genome-wide DNA methylation profiling of peripheral leukocytes was conducted in two set of samples, a discovery set (20 medication-free patients with MDD and 19 controls) and a replication set (12 medication-free patients with MDD and 12 controls), using Infinium HumanMethylation450 BeadChips. Significant diagnostic differences in DNA methylation were observed at 363 CpG sites in the discovery set. All of these loci demonstrated lower DNA methylation in patients with MDD than in the controls, and most of them (85.7%) were located in the CGIs in the gene promoter regions. We were able to distinguish patients with MDD from the control subjects with high accuracy in the discriminant analysis using the top DNA methylation markers. We also validated these selected DNA methylation markers in the replication set. Our results indicate that multiplex DNA methylation markers may be useful for distinguishing patients with MDD from non-psychiatric controls. 相似文献
978.
979.
Hiroyuki Hirakawa Hirofumi Zempo Masahito Ogawa Ryo Watanabe Jun-ichi Suzuki Hiroshi Akazawa Issei Komuro Mitsuaki Isobe 《PloS one》2015,10(3)
Myocarditis is a critical inflammatory disorder which causes life-threatening conditions. No specific or effective treatment has been established. DPP-4 inhibitors have salutary effects not only on type 2 diabetes but also on certain cardiovascular diseases. However, the role of a DPP-4 inhibitor on myocarditis has not been investigated. To clarify the effects of a DPP-4 inhibitor on myocarditis, we used an experimental autoimmune myocarditis (EAM) model in Balb/c mice. EAM mice were assigned to the following groups: EAM mice group treated with a DPP-4 inhibitor (linagliptin) (n = 19) and those untreated (n = 22). Pathological analysis revealed that the myocardial fibrosis area ratio in the treated group was significantly lower than in the untreated group. RT-PCR analysis demonstrated that the levels of mRNA expression of IL-2, TNF-α, IL-1β and IL-6 were significantly lower in the treated group than in the untreated group. Lymphocyte proliferation assay showed that treatment with the DPP-4 inhibitor had no effect on antigen-induced spleen cell proliferation. Administration of the DPP-4 inhibitor remarkably suppressed cardiac fibrosis and reduced inflammatory cytokine gene expression in EAM mice. Thus, the agents present in DPP-4 inhibitors may be useful to treat and/or prevent clinical myocarditis. 相似文献
980.
Sayuki Iijima Kentaro Matsuura Tsunamasa Watanabe Koji Onomoto Takashi Fujita Kyoko Ito Etsuko Iio Tomokatsu Miyaki Kei Fujiwara Noboru Shinkai Atsunori Kusakabe Mio Endo Shunsuke Nojiri Takashi Joh Yasuhito Tanaka 《PloS one》2015,10(2)
The levels of expression of interferon-stimulated genes (ISGs) in liver are associated with response to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV). However, associations between the responses of ISGs to IFN-based therapy and treatment efficacy or interleukin-28B (IL28B) genotype have not yet been determined. Therefore, we investigated the early responses of ISGs and interferon-lambdas (IFN-λs) in peripheral blood mononuclear cells (PBMCs) during PEG-IFN/RBV plus NS3/4 protease inhibitor (PI) therapy. We prospectively enrolled 50 chronic hepatitis C patients with HCV genotype 1, and collected PBMCs at baseline, 8 and 24 h after the initial administration of PEG-IFN/RBV/PI. Levels of mRNAs for selected ISGs and IFN-λs were evaluated by real-time PCR. All 31 patients with a favorable IL28B genotype and 13 of 19 with an unfavorable genotype achieved sustained virological responses (SVR). Levels of mRNA for A20, SOCS1, and SOCS3, known to suppress antiviral activity by interfering with the IFN signaling pathway, as well as IRF1 were significantly higher at 8 h in patients with an unfavorable IL28B genotype than in those with a favorable one (P = 0.007, 0.026, 0.0004, 0.0006, respectively), especially in the non-SVR group. Particularly, the fold-change of IRF1 at 8 h relative to baseline was significantly higher in non-SVR than in SVR cases with an unfavorable IL28B genotype (P = 0.035). In conclusion, levels of several mRNAs of genes suppressing antiviral activity in PBMCs during PEG-IFN/RBV/PI differed according to IL28B genotypes, paralleling treatment efficacy. 相似文献